-
AGE AND GENDER HETEROGENEITY IN ADVERSE DRUG REACTIONS ASSOCIATED WITH HEMP USE: EVIDENCE FROM THE FDA PHARMACOVIGILANCE DATA IN THE LAST TWO DECADES
Mar 18, 2026, 21:38 PM -
ACCESSIBILITY OF FULL VERSUS PARTIAL ORPHAN DRUGS IN CHINA: AN ANALYSIS BASED ON THE 2017-2024 NATIONAL DRUG PRICE NEGOTIATION
Mar 18, 2026, 21:38 PM -
PREPARING FOR JCA: INSIGHTS FROM FIVE-YEAR REVIEW OF NATIONAL HTA OUTCOMES
Mar 18, 2026, 21:38 PM -
THE BUDGET IMPACT OF TUMOR-TREATING FIELDS PLUS GEMCITABINE AND NAB-PACLITAXEL FOR FRONT-LINE TREATMENT OF LOCALLY ADVANCED PANCREATIC CANCER
Mar 18, 2026, 21:38 PM -
DISPARITIES IN UTILIZATION OF DIABETES COMPLICATIONS-RELATED PREVENTIVE SERVICES AMONG U.S. ADULTS WITH DIABETES: EVIDENCE FROM THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Mar 18, 2026, 21:38 PM -
AN ALGORITHM TO IDENTIFY LESS INVASIVE SURFACTANT ADMINISTRATION USING A REAL-WORLD DATABASE OF PRETERM INFANTS
Mar 18, 2026, 21:38 PM -
HEALTH RELATED QUALITY OF LIFE IN ULCERATIVE COLITIS: A SYSTEMATIC EVALUATION OF INSTRUMENTS AND THEIR PSYCHOMETRIC VALIDATION
Mar 18, 2026, 21:38 PM -
COMPARING SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2I) VERSUS RENIN-ANGIOTENSIN SYSTEM INHIBITOR (RASI) IN HEART FAILURE PATIENTS WITH ALZHEIMER’S DISEASE AND RELATED DEMENTIA (ADRD)
Mar 18, 2026, 21:38 PM -
EFFICACY AND MARKET SHARE OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS FOR CURRENT OFF-LABEL USES: A TARGETED LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
THE COST-EFFECTIVENESS OF INCLUSION OF JERYL LYNN MUMPS VACCINE IN THE MEASLES-RUBELLA ROUTINE IMMUNISATION SCHEDULE AMONG CHILDREN IN INDIA
Mar 18, 2026, 21:38 PM -
COST-EFFECTIVENESS OF BIOLOGIC THERAPIES FOR SEVERE ASTHMA: A SYSTEMATIC LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
HEALTHCARE UTILIZATION AND COSTS OF CT-BASED ROBOTIC-ARM ASSISTED VERSUS MANUAL TOTAL KNEE ARTHROPLASTY COHORTS: REAL-WORLD EVIDENCE FROM THE PREMIER HEALTHCARE DATABASE
Mar 18, 2026, 21:38 PM -
REAL-WORLD DEMOGRAPHIC AND TREATMENT CHARACTERISTICS OF PATIENTS WITH CONGENITAL MYASTHENIC SYNDROME IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
A HOSPITAL-LEVEL COST CALCULATOR COMPARING RUBIDIUM POSITRON EMISSION TOMOGRAPHY (PET) AND FLURPIRIDAZ PET FOR MYOCARDIAL PERFUSION IMAGING: A CONCEPTUAL FRAMEWORK
Mar 18, 2026, 21:38 PM -
USE OF ITEM RESPONSE THEORY TO CREATE MULTI-DIMENSIONAL MEASURES OF FINANCIAL TOXICITY IN CANCER
Mar 18, 2026, 21:38 PM -
COPULA-BASED ANALYSISOF MULTI-DOMAINHEALTH-RELATEDQUALITY OF LIFE (HRQOL)INCRIMINAL-LEGALSYSTEMINVOLVED POPULATIONS
Mar 18, 2026, 21:38 PM -
REAL-WORLD TRANSITION PROBABILITY ANALYSES AMONG UNRESECTABLE LOCALLY ADVANCED (LA) ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION CANCER (EC/GEJC) PATIENTS TREATED WITH DEFINITIVE CHEMORADIOTHERAPY (DCRT) AT COMMUNITY ONCOLOGY CENTERS
Mar 18, 2026, 21:38 PM -
LIVING COST-EFFECTIVENESS SEQUENCE ANALYSIS (SEQUENCE-CEA) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PAYER-CENTRIC FRAMEWORK FOR DYNAMIC FORMULARY DECISION MAKING
Mar 18, 2026, 21:38 PM -
THE IMPACT OF PHYSICAL FUNCTION ON HEALTHCARE RESOURCE USE AND CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE: A UK BIOBANK STUDY
Mar 18, 2026, 21:38 PM -
CLINICAL VALIDATION OF A MACHINE-LEARNING-ENRICHED IMMUNE-MEDIATED NECROTIZING MYOPATHY COHORT USING LINKED LABORATORY AND CLAIMS DATA
Mar 18, 2026, 21:38 PM
